谷氨酸的
神经科学
NMDA受体
代谢型谷氨酸受体
精神科
药理学
心理学
作者
Madeeha Nasir,Daniel Trujillo,Jessica L.S. Levine,Jennifer B. Dwyer,Zachary W. Rupp,Michael H. Bloch
标识
DOI:10.3389/fpsyt.2020.548505
摘要
Serotonin reuptake inhibitors and benzodiazepines are evidence-based pharmacological treatments for Anxiety Disorders targeting serotonin and GABAergic systems, respectively. Although clearly effective, these medications fail to improve anxiety symptoms in a significant proportion of patients. New insights into the glutamate system have directed attention toward drugs that modulate glutamate as potential alternative treatments for anxiety disorders. Here we summarize the current understanding of the potential role of glutamate neurotransmission in anxiety disorders and highlight specific glutamate receptors that are potential targets for novel anxiety disorder treatments. We also review clinical trials of medications targeting the glutamate system in DSM-5 anxiety disorders. Understanding the role of the glutamate system in the pathophysiology of anxiety disorder may aid in developing novel pharmacological agents that are effective in treating anxiety disorders.
科研通智能强力驱动
Strongly Powered by AbleSci AI